Table 1.
Changes in clinical laboratory values from baseline
| Baseline | Change at week 52 from baseline | P‐value | |
|---|---|---|---|
| HbA1c (%) | 7.5 ± 1.2 | −0.7 ± 1.1 | <0.001 |
| GA (%) | 20.3 ± 5.0 | −2.2 ± 3.8 | <0.001 |
| FPG (mg/dL) | 141.2 ± 43.6 | −17.7 ± 35.3 | <0.001 |
| PPG (mg/dL) | 187.7 ± 73.2 | −32.6 ± 70.9 | <0.001 |
| Bodyweight (kg) | 59.8 ± 11.2 | −0.3 ± 2.5 | <0.001 |
| BMI (kg/m2) | 24.2 ± 3.6 | −0.1 ± 1.0 | <0.001 |
| SBP (mmHg) | 133.8 ± 16.2 | −2.0 ± 15.4 | <0.001 |
| DBP (mmHg) | 73.5 ± 10.5 | −1.3 ± 10.1 | <0.001 |
| AST (IU/L) | 25.3 ± 13.6 | −0.3 ± 11.1 | 0.095 |
| ALT (IU/L) | 23.6 ± 17.2 | −1.7 ± 15.4 | <0.001 |
| γGTP (mg/dL) | 41.5 ± 63.1 | −3.9 ± 34.8 | <0.001 |
| Urine Alb/Cre ratio (mg/g Cr) | 69.1 ± 292.5 | 4.6 ± 226.4 | 0.61 |
Data are shown as mean ± standard deviation. Dose of sitagliptin (n) at baseline: 12.5 mg (15 patients), 25 mg (943 patients), 50 mg (4,107 patients) and 100 mg (65 patients). γGTP, gamma‐glutamyl transpeptidase; ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting plasma glucose; GA, glycoalbumin; PPG, postprandial plasma glucose; SBP, systolic blood pressure; Urine Alb/Cre ratio, urine albumin/creatinine ratio.